Correlation analyses were performed for overall scores on each neuropsychological test and retest reliability was assessed via regression analyses. The validation study involved 100 participants age 55 and above who completed two testing sessions one-to-two weeks apart using both Cognivue Clarity and MoCA. Fred Ma, the paper’s first author and chief medical officer and senior vice president at Cognivue.
It further reinforces the findings of prior studies of the world’s first FDA-cleared computerized test of cognitive function and affirms the technology’s use in today’s evolving healthcare environments,” said Dr. “This study further demonstrates that Cognivue’s technology is the most reliable, non-biased, objective assessment of cognitive function decline. The digital system is engineered to eliminate bias and variability throughout the test that establishes cognitive baselines and provide a concurrent monitoring vehicle for the evaluation and treatment of cognitive issues over time. 1Ĭognivue® technologies are designed to provide healthcare providers a useful tool for cognitive evaluation and diagnosis of various neurodegenerative and neuropsychological disorders. The peer-reviewed paper is now available via open access from Neurological Sciences and Neurosurgery. announced the publication of its clinical validation study showing its technology equally as effective as the Montreal Cognitive Assessment (MoCA) with superior test-retest reliability. ROCHESTER, N.Y., August 20, 2021-Neuroscience company Cognivue, Inc. Study Published in Neurological Sciences and Neurosurgery Shows FDA-Cleared Technology as Having Superior Test-Retest Reliability Affirms Use as Efficient, Easy-to-Use Alternative to Traditional Pencil-and-Paper Assessment Methods
0 kommentar(er)
